Loading..
  • Oasmia logo
  • Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact
  • About Us
    • Purpose, Vision & Mission
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Collaborations and partners
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Our Science
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Portfolio
      • Docetaxel Micellar
      • XR-19
    • Animal Health
    • Research and development
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Investment case
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Contact
  • Contact

General Meeting

The General Meeting is Oasmia’s highest decision-making body, at which the shareholders exercise their voting rights.

At the Annual General Meeting (AGM), which must be held within six months of the end of the financial year, shareholders resolves on key issues, such as the adoption of income statements and balance sheets, appropriation of the company’s result, discharge from liability of members of the Board of Directors and the CEO, election of members of the Board of Directors and auditors and remuneration to the Board of Directors and the auditor.

No later than in conjunction with the publication of the third-quarter report, the date and place of the AGM is published on the company’s website. The notice of the AGM is published at the earliest six weeks, but no later than four weeks, before the date of the AGM.

In addition to the AGM, Extraordinary General Meetings may be convened when required.

Shareholders who are registered in Euroclear Sweden AB’s share register as of the record day and, by the date specified in the notice, have reported their intention to attend may participate and vote at the General Meeting, in person or by a representative.
Shareholders who wish to have a matter brought before the General Meeting must submit a written request to the Board of Directors. Normally, the request must be received by the Board of Directors no later than seven weeks prior to the General Meeting. Shareholders may submit their requests by e-mail to styrelse@oasmia.com or by ordinary mail to the following address:

Oasmia Pharmaceutical AB
Att: The Board of Directors
Vallongatan 1
SE 752 28 Uppsala
Sweden

2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2008
  • 2007
  • 2006
  • All years
May 27, 2021

Annual General Meeting 2021

September 9, 2020

Annual General Meeting 2020

May 14, 2020

Extraordinary General Meeting 2020

November 6, 2019

Extraordinary General Meeting November 6, 2019

September 26, 2019

Annual General Meeting 2019

March 19, 2019

Extraordinary General Meeting 2019

September 25, 2018

Annual General Meeting 2018

September 25, 2017

Annual General Meeting 2017

June 2, 2017

Extraordinary General Meeting June 2017

November 21, 2016

Extraordinary General Meeting November 2016

September 26, 2016

Annual General Meeting 2016

September 28, 2015

Annual General Meeting 2015

May 28, 2015

Extraordinary General Meeting May 2015

September 29, 2014

Annual General Meeting 2014

September 30, 2013

Annual General Meeting 2013

September 24, 2012

Annual General Meeting 2012

September 30, 2011

Annual General Meeting 2011

September 28, 2010

Annual General Meeting 2010

September 11, 2008

Annual General Meeting 2008

September 7, 2007

Annual General Meeting 2007

September 15, 2006

Annual General Meeting 2006

Calendar

  • 19 Feb
    Year-end report May – December 2020
  • 26 Apr
    Annual Report 2020
  • 27 May
    Interim Report January – March 2021
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR-17.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Oasmia Pharmaceutical AB
Vallongatan 1, 752 28
Uppsala, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@oasmia.com